参考文献
(在框内滑动手指即可浏览)
[1] Siegel RL,Miller KD,Wagle NS,et al. Cancer statistics,2023[J]. CA Cancer J Clin,2023,73(1): 17-48.
[2] Sung H,Ferlay J,Siegel RL,et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3): 209-249.
[3] Zeng H,Chen W,Zheng R,et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health,2018,6(5): e555-e567.
[4] Frei E 3rd. Clinical cancer research: An embattled species[J]. Cancer,1982,50(10): 1979-1992.
[5] 中华医学会外科学分会胰腺外科学组,中国研究型医院学会胰腺疾病专业委员会. 中国胰腺癌新辅助治疗指南(2020版)[J]. 协和医学杂志,2020,11(5):547-558.
[6] Wu W,Miao Y,Yang Y,et al. Real-world study of surgical treatment of pancreatic cancer in China: Annual report of China Pancreas Data Center (2016-2020)[J]. J Pancreatol,2022,5(1): 1-9.
[7] Versteijne E,van Dam JL,Suker M,et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the dutch randomized PREOPANC trial[J]. J Clin Oncol,2022,40(11): 1220-1230.
[8] Versteijne E,Suker M,Groothuis K,et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol,2020,38(16): 1763-1773.
[9] Reni M,Balzano G,Zanon S,et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): A randomised,open-label,phase 2-3 trial[J]. Lancet Gastroenterol Hepatol,2018,3(6): 413-423.
[10] Sohal DPS,Duong M,Ahmad SA,et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial[J]. JAMA Oncol,2021,7(3): 421-427.
[11] Seufferlein T,Uhl W,Kornmann M,et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX):A randomized phase Ⅱ trial of the AIO pancreatic cancer group[J]. Ann Oncol,2023,34(1): 91-100.
[12] Uson Junior PLS,Dias ESD,de Castro NM,et al. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and Meta-analysis of randomized controlled trials[J]. ESMO Open,2023,8(1): 100771.
[13] Katz MHG,Shi Q,Meyers J,et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 pandomized clinical trial[J]. JAMA Oncol,2022,8(9): 1263-1270.
[14] Hammel P,Huguet F,van Laethem JL,et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial[J]. JAMA,2016,315(17): 1844-1853.
[15] Reyngold M,O'Reilly EM,Varghese AM,et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer[J]. JAMA Oncol,2021,7(5): 735-738.
[16] Reames BN,Blair AB,Krell RW,et al. Management of locally advanced pancreatic cancer: Results of an international survey of current practice[J]. Ann Surg,2021,273(6): 1173-1181.
[17] Truty MJ,Kendrick ML,Nagorney DM,et al. Factors predicting response,perioperative outcomes,and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer[J]. Ann Surg,2021,273(2): 341-349.
[18] 张太平,刘悦泽,任博. 胰腺癌全程新辅助治疗的现状及挑战[J]. 中华消化外科杂志,2022,21(4): 461-464.
[19] 赵姿璇,肖剑春,张太平,等. 胰腺癌新辅助治疗后可切除性评估研究进展及争议[J]. 中国实用外科杂志,2021,41(4):463-468.
[20] Hank T,Klaiber U,Hinz U,et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer[J]. Ann Surg,2022,277(5): e1089-1098.
[21] Strickler JH,Satake H,George TJ,et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med,2023,388(1): 33-43.
[22] Kemp SB,Cheng N,Markosyan N,et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer[J]. Cancer Discov,2023,13(2): 298-311.